scholarly journals Autoimmune Hemolytic Anemia as Presenting Symptom of Hodgkin Lymphoma

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Nicholas B. Burley ◽  
Paul S. Dy ◽  
Suraj Hande ◽  
Shreyas Kalantri ◽  
Chirayu Mohindroo ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Viral Infections ◽  
Autoimmune Disorders ◽  
Lymphoproliferative Disorders ◽  
Lymphocytic Leukemia ◽  
Stage Iii ◽  
Nodular Sclerosis ◽  
Non Hodgkin Lymphoma

Autoimmune hemolytic anemia (AIHA) is related to an underlying condition in an estimated 50 to 60%, while the remaining is idiopathic, as a result of a combination of immune activation, deficiency, or dysregulation. AIHA is associated with viral infections, autoimmune disorders, immunodeficiencies, lymphoproliferative disorders, and pregnancy. AIHA has predictive properties and may be a harbinger of future lymphoproliferative disorders in up to 20% of AIHA cases. Autoimmune hemolytic anemia (AIHA) has been associated with lymphoproliferative disorders particularly chronic lymphocytic leukemia and non-Hodgkin lymphoma. Rarely is it seen in Hodgkin disease. In the following report, we describe the presentation of AIHA, ultimately resulting in the diagnosis of nodular sclerosis Hodgkin lymphoma (stage III). From the limited reports and reviews available, it is understood that advanced Hodgkin (stage III or IV) of nodular sclerosis (NS) or mixed cellularity (MC) types portend a stronger affiliation to AIHA. The majority of AIHA-associated Hodgkin lymphoma presents as stage III or IV disease with the hemolysis being the presenting symptom, as in this case. The mainstay of AIHA therapy has been corticosteroids; however, this first-line regimen appears to be less effective when treating AIHA in the setting of HL. The exact mechanism of AIHA related to HL is unclear, and it may be thought to be that tumor cell produced autoantibodies. Other hypotheses include paraneoplastic phenomena or more, perhaps immunity to tumor cells may cross-react with antigens on the red cells. Although these mechanisms require further investigation, the relationship of the AIHA and HL represents a piece to a larger puzzle between autoimmune disorders and lymphoproliferative conditions.

scholarly journals Autoimmune Hemolytic Anemia and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Rare Association

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Géraldine Salmeron ◽  
Thierry Jo Molina ◽  
Claire Fieschi ◽  
Anne-Marie Zagdanski ◽  
Pauline Brice ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Mediastinal Lymph Node ◽  
Hemoglobin Level ◽  
Lymphocytic Leukemia ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Non Hodgkin Lymphoma ◽  
Positron Emission

Autoimmune hemolytic anemia (AIHA) has been associated with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and classical Hodgkin lymphoma, but to the best of our knowledge, the association of AIHA and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) has not been reported previously. A 20-year-old woman presented with conjunctival jaundice, fever, asthenia, and hemoglobin 9.2 g/dL revealing IgG-mediated warm antibody AIHA. Computed tomography (CT) scan and positron-emission tomography (PET) scan showed mediastinal and axillary lymph nodes with increased [18F]-fluorodeoxyglucose uptake. A mediastinal lymph node was biopsied during mediastinoscopy, and NLPHL was diagnosed by an expert hematopathologist. The hemoglobin level declined to 4.6 g/dL. The treatment consisted of four 28-day cycles of R-ABVD (rituximab 375 mg/m2IV, adriamycin 25 mg/m2IV, bleomycin 10 mg/m2IV, vinblastine 6 mg/m2IV, and dacarbazine 375 mg/m2IV, each on days 1 and 15). Prednisone was progressively tapered over 10 weeks. After the first chemotherapy cycle, the hemoglobin level rose to 12 g/dL. After the four cycles, PET and CT scans showed complete remission (CR). At the last followup (4 years), AIHA and NLPHL were in sustained CR.

Autoimmune Hemolytic Anemia with Myelodysplastic Features Followed by Bilateral Adrenal Non-Hodgkin Lymphoma: A Case Report and Review of the Literature

2004 ◽  
Vol 45 (11) ◽  
pp. 2333-2338 ◽  
Author(s):  
Evangelos Terpos ◽  
Stamatios Theocharis ◽  
Fotios Panitsas ◽  
Theodoros Philippidis ◽  
Epaminondas Kotronis ◽  
...  
Keyword(s):  
Case Report ◽  
Hodgkin Lymphoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Review Of The Literature ◽  
Non Hodgkin Lymphoma

scholarly journals Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia

Medicine ◽  
2020 ◽  
Vol 99 (7) ◽  
pp. e19015
Author(s):  
Ji-cheng Zhou ◽  
Mei-qing Wu ◽  
Zheng-mian Peng ◽  
Wei-hua Zhao ◽  
Zhen-jie Bai
Keyword(s):  
Hodgkin Lymphoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Clinical Analysis ◽  
Non Hodgkin Lymphoma

scholarly journals Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia

Pharmacology ◽  
2020 ◽  
Vol 105 (11-12) ◽  
pp. 630-638
Author(s):  
Tahseen Hamamyh ◽  
Mohamed A. Yassin
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Hemolytic Anemia ◽  
Chronic Myelogenous Leukemia ◽  
Autoimmune Hemolytic Anemia ◽  
Myeloid Leukemia ◽  
Viral Infections ◽  
Case Reports ◽  
Chronic Phase ◽  
Lymphocytic Leukemia ◽  
Myelogenous Leukemia

<b><i>Background:</i></b> Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual. <b><i>Summary:</i></b> We reviewed case reports and series of 54 patients with chronic myeloid leukemia (CML) who developed autoimmune hemolysis between 1952 and 2018. Almost all the patients were in the chronic phase and were classified into transplant and non-transplant groups. The onset of autoimmune hemolysis was earlier in the transplant group and required second- and third-line therapy to control it. The etiology of hemolysis is poorly understood but attributed in the transplant group to immune reconstitution, viral infections, or CML relapse. On the other hand, it is thought to be related in the non-transplant group to CML medications, especially interferon. <b><i>Key Messages:</i></b> Although AIHA is uncommon in chronic myelogenous leukemia patients, it should be in the differential diagnosis list for those who develop a sudden drop in hemoglobin without a bleeding source.

scholarly journals Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Claudio Fozza ◽  
Maurizio Longinotti
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Antibody Production ◽  
Autoimmune Hemolytic Anemia ◽  
Therapeutic Approach ◽  
Lymphoproliferative Disorders ◽  
Lymphocytic Leukemia ◽  
Pathogenetic Mechanism ◽  
Anti Cd20

The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of patients. In recent years, among the more traditional therapeutic options, rituximab, an anti-CD20 monoclonal antibody, has shown interesting results in the treatment of primary AHA. Although this drug has been frequently used for AHA in patients with CLL, much less data are available on its use in NHL patients. However, considering that the main pathogenetic mechanism of AHA in course of lymphoproliferative disorders seems to be an antibody production directly or indirectly mediated by the neoplastic clone, this monoclonal antibody represents an ideal therapeutic approach. In this paper we will briefly describe some biological and clinical features of NHL-patients with AHA. We will then analyze some studies focusing on rituximab in primary AHA, finally reviewing the available literature on the use of this drug in NHL related AHA.

UCTD – A RARE CAUSE OF SECONDARY WARM AUTOIMMUNE HEMOLYTIC ANEMIA

2021 ◽  
pp. 36-37
Author(s):  
Naim M Kadri ◽  
Nirmit S Sheth ◽  
Keval R Vora
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Viral Infections ◽  
Surface Antigens ◽  
Connective Tissue Disorder ◽  
Common Type ◽  
Lymphoproliferative Disorders ◽  
Treatment Modalities ◽  
Intravascular Hemolysis ◽  
Toxic Agents

Anemia caused due to Red Blood Cell (RBC) destruction is called Hemolytic Anemia; which can be due to hemoglobinopathies, enzymopthies, autoantibodies, infections, drugs and toxic agents. Autoimmune Hemolytic Anemia (AIHA) is a type of hemolytic anemia caused by autoantobodies to RBC surface antigens causing extravascular hemolysis in most cases; but can cause intravascular hemolysis in severe cases. The antibodies are usually of warm type (IgG) but can also be of cold variant (IgM). Warm AIHA is the most common type of AIHA. It is usually of primary (idiopathic) type but it can be due to secondary causes (like viral infections, autoimmune diseases, lymphoproliferative disorders, immunodeciency states or pregnancy). Here is a case of secondary AIHA induced by Undifferentiated Connective Tissue Disorder (UCTD) which was refractory to usual treatment modalities.

scholarly journals Deep Learning for the Classification of Non-Hodgkin Lymphoma on Histopathological Images

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2419
Author(s):  
Georg Steinbuss ◽  
Mark Kriegsmann ◽  
Christiane Zgorzelski ◽  
Alexander Brobeil ◽  
Benjamin Goeppert ◽  
...  
Keyword(s):  
Deep Learning ◽  
Hodgkin Lymphoma ◽  
Expert Knowledge ◽  
B Cell Lymphoma ◽  
High Accuracy ◽  
Lymphocytic Leukemia ◽  
Non Hodgkin Lymphoma ◽  
Image Patches ◽  
Histopathological Images

The diagnosis and the subtyping of non-Hodgkin lymphoma (NHL) are challenging and require expert knowledge, great experience, thorough morphological analysis, and often additional expensive immunohistological and molecular methods. As these requirements are not always available, supplemental methods supporting morphological-based decision making and potentially entity subtyping are required. Deep learning methods have been shown to classify histopathological images with high accuracy, but data on NHL subtyping are limited. After annotation of histopathological whole-slide images and image patch extraction, we trained and optimized an EfficientNet convolutional neuronal network algorithm on 84,139 image patches from 629 patients and evaluated its potential to classify tumor-free reference lymph nodes, nodal small lymphocytic lymphoma/chronic lymphocytic leukemia, and nodal diffuse large B-cell lymphoma. The optimized algorithm achieved an accuracy of 95.56% on an independent test set including 16,960 image patches from 125 patients after the application of quality controls. Automatic classification of NHL is possible with high accuracy using deep learning on histopathological images and routine diagnostic applications should be pursued.

A CASE OF A CHRONIC LYMPHOPROLIFERATIVE DISORDER PRESENTING AS AUTOIMMUNE HEMOLYTIC ANEMIA

2021 ◽  
pp. 13-14
Author(s):  
Jessica Pereira ◽  
Aparna Pai
Keyword(s):  
Case Report ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Lymphoproliferative Disorder ◽  
Clinical Course ◽  
Lymphoproliferative Disorders ◽  
Favourable Response ◽  
Haemolytic Anemia

Lymphoproliferative disorders encompass a group of diseases with a highly variable clinical course. This is a case report of a patient who presented with haemolytic anemia initially and was subsequently diagnosed as a chronic lymphoproliferative disorder. He was treated with Rituximab to which he showed a favourable response.

Sign in / Sign up

Export Citation Format

Share Document